NUWE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nuwellis Inc (NUWE) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are some positive developments in the company's operations and financials, the lack of significant trading signals, neutral sentiment from insiders and hedge funds, and weak earnings performance make it prudent to hold off on buying this stock right now.
The MACD is positive but contracting, RSI is neutral at 60.814, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 1.152, with resistance at 1.245 and support at 1.058. Overall, the technical indicators suggest a neutral stance.
The return of experienced team members and focus on enhancing clinical and commercial capabilities for Aquadex therapy could drive future growth. Gross margin has improved significantly (up 16.93% YoY).
The company remains unprofitable with a negative net income of -$2.42M, despite a YoY improvement. EPS dropped significantly (-91.81% YoY), and there are no significant insider or hedge fund trading trends to indicate confidence in the stock.
In Q4 2025, revenue increased by 4.39% YoY to $2.42M, and net income improved by 64.92% YoY but remains negative at -$2.42M. Gross margin increased to 68.23%, but EPS dropped sharply to -1.5.
No analyst rating or price target changes provided. Neutral sentiment from insiders and hedge funds.
